Coya Therapeutics (COYA) Cash & Equivalents (2021 - 2026)

Coya Therapeutics has reported Cash & Equivalents for 6 years, with the latest figure at $50.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 42.76% year-over-year to $50.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.7 million (up 42.76% YoY) and the FY2025 annual result came in at $46.8 million, up 22.13% from the prior year.
• Cash & Equivalents climbed to $50.7 million in Q1 2026 per COYA's latest filing, from $46.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $50.7 million in Q1 2026 and troughed at $5.9 million in Q4 2022.
• A 5-year average of $29.4 million and a median of $31.8 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 449.86% in 2023, then declined 18.7% in 2025.
• Over 5 years, Cash & Equivalents stood at $5.9 million in 2022, then surged by 449.86% to $32.6 million in 2023, then climbed by 17.51% to $38.3 million in 2024, then rose by 22.13% to $46.8 million in 2025, then grew by 8.33% to $50.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $50.7 million, $46.8 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.